跳至主要内容
临床试验/JPRN-UMIN000012032
JPRN-UMIN000012032已完成1 期

Phase Ib study of 131I-metaiodobenzylguanidine(MIBG) therapy with Valproic Acid(VPA) for high risk or recurrent neuroblastoma - Phase Ib study of VPA and 131I-MIBG for recurrent / resistant neuroblastoma

ational Cancer Research Center Hospital0 个研究点目标入组 10 人开始时间: 2013年10月14日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
3years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. active double cancer(synchronous double cancer and metachronous double cancer within 5 disease -free years),excluding carcinoma In situ(lesions equal to Intraepithelial or intramucosal Cancer)judged to have been cured with local treatment 2. active infection requiring systemic medication 3. abnormality in electrocardiogram tested within 28 days,requiring intervention 4. Psychosis which is not appropriate for participating in this study

研究者

发起方
ational Cancer Research Center Hospital

相似试验